Jennifer E. Cole

Jennifer E. Cole

Auto-generated profile, based on publicly available information

Jennifer E. Cole

Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JCJennifer E. Cole
Jennifer E. Cole
TNTina J. Navin
Tina J. Navin
ACAmanda J. Cross
Amanda J. Cross
MGMichael E. Goddard
Michael E. Goddard
LALena Alexopoulou
Lena Alexopoulou
CMClaudia Monaco
Claudia Monaco
The critical role of Toll-like receptors (TLRs) in mammalian host defense has been extensively explored in recent years. The capacity of about 10 TLRs to recognize conserved patterns on many bacterial and viral pathogens is remarkable. With so few receptors, cross-reactivity with self-tissue components often occurs. Previous studies have frequently assigned detrimental roles to TLRs, in particular to TLR2 and TLR4, in immune and cardiovascular disease. Using human and murine systems, we have investigated the consequence of TLR3 signaling in vascular disease. We compared the responses of human atheroma-derived smooth muscle cells (AthSMC) and control aortic smooth muscle cells (AoSMC) to various TLR ligands. AthSMC exhibited a specific increase in TLR3 expression and TLR3-dependent functional responses. Intriguingly, exposure to dsRNA in vitro and in vivo induced increased expression of both pro- and anti-inflammatory genes in vascular cells and tissues. Therefore, we sought to assess the contribution of TLR3 signaling in vivo in mechanical and hypercholesterolemia-induced arterial injury. Surprisingly, neointima formation in a perivascular collar-induced injury model was reduced by the systemic administration of the dsRNA analog Poly(I:C) in a TLR3-dependent manner. Furthermore, genetic deletion of TLR3 dramatically enhanced the development of elastic lamina damage after collar-induced injury. Accordingly, deficiency of TLR3 accelerated the onset of atherosclerosis in hypercholesterolemic ApoE −/− mice. Collectively, our data describe a protective role for TLR signaling in the vessel wall.

1 January 2010 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
JCJennifer E. Cole
Jennifer E. Cole
EGEktoras Georgiou
Ektoras Georgiou
CMClaudia Monaco
Claudia Monaco
Inflammation drives atherosclerosis. Both immune and resident vascular cell types are involved in the development of atherosclerotic lesions. The phenotype and function of these cells are key in determining the development of lesions. Toll-like receptors are the most characterised innate immune receptors and are responsible for the recognition of exogenous conserved motifs on pathogens, and, potentially, some endogenous molecules. Both endogenous and exogenous TLR agonists may be present in atherosclerotic plaques. Engagement of toll-like receptors on immune and resident vascular cells can affect atherogenesis as signalling downstream of these receptors can elicit proinflammatory cytokine release, lipid uptake, and foam cell formation and activate cells of the adaptive immune system. In this paper, we will describe the expression of TLRs on immune and resident vascular cells, highlight the TLR ligands that may act through TLRs on these cells, and discuss the consequences of TLR activation in atherosclerosis.

5 October 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JCJennifer E. Cole
Jennifer E. Cole
NANagore Astola
Nagore Astola
ACAdam Cribbs
Adam Cribbs
MGMichael E. Goddard
Michael E. Goddard
IPInhye Park
Inhye Park
CMClaudia Monaco
Claudia Monaco
Significance: Inflammation is an important component of the pathogenesis of cardiovascular disease, the world’s biggest killer. No antiinflammatory treatments have yet been developed to treat cardiovascular disease. Indoleamine 2,3-dioxygenase (IDO) is a critical enzyme in the metabolism of tryptophan that has been shown to be immune-regulatory in many diseases. ApoE−/−mice deficient in IDO (ApoE−/−Indo−/−) developed larger atherosclerotic lesions and an unfavorable lesion phenotype that may predispose to cardiovascular complications. Furthermore, administration of an orally active synthetic tryptophan metabolite (3,4-DAA) reduced disease development in mice and cytokine production in human atheroma. Our data demonstrate that endogenous production of tryptophan metabolites via IDO is an essential feedback loop that controls atherogenesis and athero-inflammation, defining a path toward the development of new therapeutics.

9 February 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
AEAndreas Edsfeldt
Andreas Edsfeldt
MSMaarten Swart
Maarten Swart
PSPratibha Singh
Pratibha Singh
LDLea Dib
Lea Dib
JSJiangming Sun
Jiangming Sun
CMClaudia Monaco
Claudia Monaco
Inflammation is a key factor in atherosclerosis. The transcription factor interferon regulatory factor-5 (IRF5) drives macrophages towards a pro-inflammatory state. We investigated the role of IRF5 in human atherosclerosis and plaque stability. Bulk RNA sequencing from the Carotid Plaque Imaging Project biobank were used to mine associations between major macrophage associated genes and transcription factors and human symptomatic carotid disease. Immunohistochemistry, proximity extension assays, and Helios cytometry by time of flight (CyTOF) were used for validation. The effect of IRF5 deficiency on carotid plaque phenotype and rupture in ApoE−/− mice was studied in an inducible model of plaque rupture. Interferon regulatory factor-5 and ITGAX/CD11c were identified as the macrophage associated genes with the strongest associations with symptomatic carotid disease. Expression of IRF5 and ITGAX/CD11c correlated with the vulnerability index, pro-inflammatory plaque cytokine levels, necrotic core area, and with each other. Macrophages were the predominant CD11c-expressing immune cells in the plaque by CyTOF and immunohistochemistry. Interferon regulatory factor-5 immunopositive areas were predominantly found within CD11c+ areas with a predilection for the shoulder region, the area of the human plaque most prone to rupture. Accordingly, an inducible plaque rupture model of ApoE−/−Irf5−/− mice had significantly lower frequencies of carotid plaque ruptures, smaller necrotic cores, and less CD11c+ macrophages than their IRF5-competent counterparts. Using complementary evidence from data from human carotid endarterectomies and a murine model of inducible rupture of carotid artery plaque in IRF5-deficient mice, we demonstrate a mechanistic link between the pro-inflammatory transcription factor IRF5, macrophage phenotype, plaque inflammation, and its vulnerability to rupture. Macrophages perform both pro- and anti-atherogenic functions depending on their transcriptional status and activation. Using human carotid endarterectomies and a murine model of inducible rupture of carotid plaque, we show that the transcription factor interferon regulatory factor-5 (IRF5) promotes macrophage activation with the production of chemokines CCL2 and CCL4, and the expression of the integrin CD11c ,while it disables the production of proteins required for the uptake of apoptotic cells within the plaque (efferocytosis) such as MFEG8 and the integrin ITGB3. In doing so, IRF5 promotes inflammation and increases the necrotic core size enhancing plaque vulnerability to rupture. MFGE8, Milk fat globule—epidermal growth factor—factor VIII; CCL2, C–C motif chemokine ligand 2; CCL4, C–C motif chemokine ligand 4; ITGB3, Integrin subunit beta 3.

1 January 2015 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
PBPaul A. Blair
Paul A. Blair
CLChristoph Leib
Christoph Leib
MGMichael E. Goddard
Michael E. Goddard
ERElizabeth C. Rosser
Elizabeth C. Rosser
IPInhye Park
Inhye Park
CMClaudia Monaco
Claudia Monaco
Whilst innate B1-B cells are atheroprotective, adaptive B2-B cells are considered pro-atherogenic. Different subsets of B regulatory cells (Breg) have been described. In experimental arthritis and lupus-like disease, Breg are contained within the CD21hiCD23hiCD24hi B cell pool. The existence and role of Breg in vascular disease is not known. We sought to investigate the existence, identity and location of Breg in vascular disease. The representation of B2-B cell subsets in the spleens and lymph nodes (LNs) of Apolipoprotein E-/- (ApoE-/-) mice compared to controls was characterised by flow cytometry. Additionally, we utilised a model of neointima formation based on the placement of a perivascular collar around the carotid artery in ApoE-/- mice to ascertain whether B cells and B cell subsets confer protection against lesion development. Adoptive transfer of B cells was performed from wild type or genetically modified mice. We showed that CD21hiCD23hiCD24hi B cells are unexpectedly increased in the draining LNs of ApoE-/- mice. Adoptive transfer of LN-derived B2-B cells or purified CD21hiCD23hiCD24hi B cells to syngeneic mice reduced lesion size and inflammation without changing serum cholesterol levels. Follicular B2-B cells did not confer protection. IL-10 blockade or transfer of IL10-deficient B cells prevented LN-derived B cell-mediated protection. This is the first identification of a specific LN-derived B2-Breg subset that confers IL-10 mediated protection from neointima formation. This may open the way for immune modulatory approaches in cardiovascular disease.

11 January 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
IPInhye Park
Inhye Park
MGMichael E. Goddard
Michael E. Goddard
JCJennifer E. Cole
Jennifer E. Cole
NZNatacha Zanin
Natacha Zanin
LLLeo-Pekka Lyytikäinen
Leo-Pekka Lyytikäinen
CMClaudia Monaco
Claudia Monaco
Macrophages are integral to the pathogenesis of atherosclerosis, but the contribution of distinct macrophage subsets to disease remains poorly defined. Using single cell technologies and conditional ablation via aLysMCre+Clec4a2flox/DTRmouse strain, we demonstrate that the expression of the C-type lectin receptor CLEC4A2 is a distinguishing feature of vascular resident macrophages endowed with athero-protective properties. Through genetic deletion and competitive bone marrow chimera experiments, we identify CLEC4A2 as an intrinsic regulator of macrophage tissue adaptation by promoting a bias in monocyte-to-macrophage in situ differentiation towards colony stimulating factor 1 (CSF1) in vascular health and disease. During atherogenesis, CLEC4A2 deficiency results in loss of resident vascular macrophages and their homeostatic properties causing dysfunctional cholesterol metabolism and enhanced toll-like receptor triggering, exacerbating disease. Our study demonstrates that CLEC4A2 licenses monocytes to join the vascular resident macrophage pool, and that CLEC4A2-mediated macrophage homeostasis is critical to combat cardiovascular disease.